NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Hepatitis CLiver Disease

Interventions

DRUG

Alisporivir

Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration

DRUG

Ribavirin

Ribavirin tablets of various strengths for oral administration

DRUG

Peg-IFNα2a

Peg-IFNα2a solution for subcutaneous injection

Trial Locations (25)

10969

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

20099

Novartis Investigative Site, Hamburg

20246

Novartis Investigative Site, Hamburg

24146

Novartis Investigative Site, Kiel

30625

Novartis Investigative Site, Hanover

40225

Novartis Investigative Site, Düsseldorf

50937

Novartis Investigative Site, Cologne

60590

Novartis Investigative Site, Frankfurt

79106

Novartis Investigative Site, Freiburg im Breisgau

81377

Novartis Investigative Site, München

97080

Novartis Investigative Site, Würzburg

15-540

Novartis Investigative Site, Bialystok

20-079

Novartis Investigative Site, Lublin

01-201

Novartis Investigative Site, Warsaw

416 85

Novartis Investigative Site, Gothenburg

SE-971 80

Novartis Investigative Site, Luleå

221 85

Novartis Investigative Site, Lund

SE-205 02

Novartis Investigative Site, Malmo

141 86

Novartis Investigative Site, Stockholm

901 85

Novartis Investigative Site, Umeå

GU16 7UJ

Novartis Investigative Site, Frimley

B15 2TT

Novartis Investigative Site, Birmingham

E1 1BB

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London